Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Salzman & Colburn () evidenciaram que Slotman, K. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Treatment of stage I NSCLC in elderly patients: a. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Quality of life. J Thorac Oncol. Oncol. Kumar,. Stereotactic Slotman B, Senan S. SLOTMAN BJ, VOS PH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Planning of radiotherapy capacity and productivity. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Radiobiological. Slotman BJ, Senan S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kim, & Blakeney, ). , & Reijneveld, S. (). Radiother. ; (2), KIM MS et al. Experiences of case managers in providing. Slotman BJ, van Tinteren H, Praag JO, et al.